Are Women Living With Obesity More Responsive to GLP ‐1 Receptor Agonists? A Potential Signal From Trial‐Level and Within‐Trial Analyses

Résumé fourni par la source

Barbara McGowan has received speaker and/or advisory fees from Novo Nordisk, Eli-Lilly, Astra Zeneca, Janssen, Pfizer, MSD and a research grant from Novo Nordisk. B.M. is a shareholder of Reset Health. Andreea Ciudin has received speaking fees from Astra Zeneca, Boehringer-Ingelheim, Eli-Lilly, Novo Nordisk, Sanofi, Menarini and research grants from Eli Lilly, NovoNordisk and Menarini. Member of the DMC of Boehringer Ingelheim. Jennifer L. Baker (J.L.B.) has received a consulting fee and is an advisory board member for Novo Nordisk A/S with fees paid to her institution. Simona Bertoli has no COI to declare. Matteo Monami has received speaking fees from Astra Zeneca, Boehringer-Ingelheim, Eli-Lilly and Novo Nordisk. Edoardo Mannucci reports consultancy fees from Merck and Novartis, speaking fees from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Sanofi and Novartis, and research grants from Merck, Novartis and Takeda. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.70956. Table S1: Principal characteristics of the included trials (n = 34). Figure S1: Within-trial interaction effects for sex differences in weight loss with GLP-1 receptor agonists. Panel A. Primary within-trial analysis including studies available within the predefined search window. Panel B. Post hoc sensitivity analysis additionally including sex-stratified data from ATTAIN-1 (orforglipron). Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.